PTCT Relative Valuation
PTCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTCT is overvalued; if below, it's undervalued.
Historical Valuation
PTC Therapeutics Inc (PTCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -11.85. The fair price of PTC Therapeutics Inc (PTCT) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 77.85 USD , PTC Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：77.85
Fair
Undervalued
-49.32
PE
1Y
3Y
5Y
Trailing
Forward
146.21
EV/EBITDA
PTC Therapeutics Inc. (PTCT) has a current EV/EBITDA of 146.21. The 5-year average EV/EBITDA is 19.89. The thresholds are as follows: Strongly Undervalued below -368.78, Undervalued between -368.78 and -174.44, Fairly Valued between 214.22 and -174.44, Overvalued between 214.22 and 408.56, and Strongly Overvalued above 408.56. The current Forward EV/EBITDA of 146.21 falls within the Historic Trend Line -Fairly Valued range.
-183.59
EV/EBIT
PTC Therapeutics Inc. (PTCT) has a current EV/EBIT of -183.59. The 5-year average EV/EBIT is -18.65. The thresholds are as follows: Strongly Undervalued below -101.16, Undervalued between -101.16 and -59.91, Fairly Valued between 22.60 and -59.91, Overvalued between 22.60 and 63.86, and Strongly Overvalued above 63.86. The current Forward EV/EBIT of -183.59 falls within the Strongly Undervalued range.
6.91
PS
PTC Therapeutics Inc. (PTCT) has a current PS of 6.91. The 5-year average PS is 4.35. The thresholds are as follows: Strongly Undervalued below 1.45, Undervalued between 1.45 and 2.90, Fairly Valued between 5.80 and 2.90, Overvalued between 5.80 and 7.25, and Strongly Overvalued above 7.25. The current Forward PS of 6.91 falls within the Overvalued range.
-42.68
P/OCF
PTC Therapeutics Inc. (PTCT) has a current P/OCF of -42.68. The 5-year average P/OCF is -34.14. The thresholds are as follows: Strongly Undervalued below -263.05, Undervalued between -263.05 and -148.60, Fairly Valued between 80.32 and -148.60, Overvalued between 80.32 and 194.78, and Strongly Overvalued above 194.78. The current Forward P/OCF of -42.68 falls within the Historic Trend Line -Fairly Valued range.
26.61
P/FCF
PTC Therapeutics Inc. (PTCT) has a current P/FCF of 26.61. The 5-year average P/FCF is 33.47. The thresholds are as follows: Strongly Undervalued below -457.41, Undervalued between -457.41 and -211.97, Fairly Valued between 278.92 and -211.97, Overvalued between 278.92 and 524.36, and Strongly Overvalued above 524.36. The current Forward P/FCF of 26.61 falls within the Historic Trend Line -Fairly Valued range.
PTC Therapeutics Inc (PTCT) has a current Price-to-Book (P/B) ratio of -39.95. Compared to its 3-year average P/B ratio of -8.76 , the current P/B ratio is approximately 355.96% higher. Relative to its 5-year average P/B ratio of 90.06, the current P/B ratio is about -144.36% higher. PTC Therapeutics Inc (PTCT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.26%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -5.40% , the current FCF yield is about -100.00% lower.
-39.95
P/B
Median3y
-8.76
Median5y
90.06
11.59
FCF Yield
Median3y
-3.26
Median5y
-5.40
Competitors Valuation Multiple
The average P/S ratio for PTCT's competitors is 0.40, providing a benchmark for relative valuation. PTC Therapeutics Inc Corp (PTCT) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 7.23%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PTCT increased by 72.46% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 3.12 to 8.71.
The secondary factor is the Revenue Growth, contributed 7.23%to the performance.
Overall, the performance of PTCT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is PTC Therapeutics Inc (PTCT) currently overvalued or undervalued?
What is PTC Therapeutics Inc (PTCT) fair value?
How does PTCT's valuation metrics compare to the industry average?
What is the current P/B ratio for PTC Therapeutics Inc (PTCT) as of Dec 05 2025?
What is the current FCF Yield for PTC Therapeutics Inc (PTCT) as of Dec 05 2025?
What is the current Forward P/E ratio for PTC Therapeutics Inc (PTCT) as of Dec 05 2025?